

## COMPANY PROFILE



**Stephanie Löwen**  
Managing Director  
stephanie.loewen@chrestos.de



**Robert Krausche**  
Managing Director  
robert.krausche@chrestos.de



**Dr. Boris Weimann**  
Managing Director  
boris.weimann@chrestos.de

## History and Mission

The feeling „This should work better“ led to the foundation of **Chrestos** in 2006. Many things have changed since then, but not our desire for innovation, or our commitment to constantly improve and develop services, processes, and working and living conditions.

Continuous improvement is our path. We advance with confidence, curiosity and anticipation, knowing this path is green.

Learn more about Chrestos: [www.chrestos.de/en/GREEN](http://www.chrestos.de/en/GREEN)

## Highlights

We are a colorful bunch. Our team, with backgrounds in statistics, data science, and natural sciences, works wholeheartedly for a better future. We love what we do!

We are a diverse team. Most of us have science backgrounds, though the modal is statistics. We are passionate about researching and developing medicines and medical devices. We strive to help improve people's quality of life and health in the long term - that's what drives us.

As a CRO, we provide services in the planning and analysis of studies in all phases of clinical and non-clinical development.



[www.bvma.de](http://www.bvma.de)

## Chrestos GmbH

Girardetstraße 1-5  
45131 Essen, Germany

Tel. +49 201 470918-50

Fax +49 201 470918-51

E-Mail: [info@chrestos.de](mailto:info@chrestos.de)

BVMA member since 2022

Audit passed in 2022

# Chrestos

DIE GRÜNE CRO



<https://chrestos.de/en/>

## Services

We offer in-depth statistical expertise with relevant software experience in statistics, programming, data science, data management, and medical writing.

We bring our services to the following areas of drug and medical device research and development:

- Preclinical development
- Pharmacokinetic and pharmacodynamic studies (Phase I)
- Proof-of-concept and dose-finding studies (Phase II)
- Market approvals based on pivotal studies (Phase III)
- Observational studies and non-interventional studies (Phase IV)
- Additional benefit assessment in the context of the AMNOG procedure

In addition, we are also active in related areas, such as registries, marketing studies, diagnostics, publication support, and exploratory analyses.

## Our Areas of Expertise

- Data Management
- Programming
- Early Development Statistics
- Late Development Statistics
- Medical Affairs
- Biomarker Statistics & Data Science
- Health Technology Assessment
- Biometrics & Diagnostics
- Medical Writing



[www.bvma.de](http://www.bvma.de)